CD47 and acute myeloid leukemia: In various xenograft tumor models using NOD-scid-IL2Rgammanull (NSG) mice, use of human CD47-blocking monoclonal antibodies has demonstrated superb efficacy against human acute lymphocytic leukemia, acute myeloid leukemia, leiomyosarcoma, and solid tumors [18, 20, 27, 28, 30, 31].